Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | VDR | P11473 | 5/20 | 0.30 |
| ▸ | AR | P10275 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9672090 | 0.68 | — | — | |
| SCHEMBL17036998 | 0.67 | LMNA (0.56) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14822990 | 0.65 | KDM4E (0.68) | ALDH1A1SMN1; SMN2MEN1KMT2AALOX15 | |
| SCHEMBL9248709 | 0.64 | HTT (0.61) | TSHRALDH1A1SMN1; SMN2NPC1TP53 | |
| SCHEMBL698450 | 0.63 | KDM4E (0.46) | TSHRALDH1A1SMN1; SMN2NPC1TP53 | |
| SCHEMBL11959217 | 0.62 | LMNA (0.58) | TSHRSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL25124050 | 0.62 | ADRB2 (0.60) | TSHRALDH1A1SMN1; SMN2TP53RAB9A | |
| SCHEMBL11960667 | 0.62 | MAPT (0.51) | ALDH1A1SMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL15677169 | 0.61 | LMNA (0.55) | TSHRALDH1A1SMN1; SMN2NPC1TP53 | |
| SCHEMBL17083481 | 0.61 | KDM4E (0.50) | TSHRALDH1A1SMN1; SMN2NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2008-09-04 | — | — | US | disclosed |
| US-7375252-B2 | Compounds and method for the inhibition of the expression of VCAM-1 | ATHEROGENICS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7189870-B2 | Compounds and methods for the inhibition of the expression of VCAM-1 | ATHEROGENIC, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060058268-A1 | Compounds and methods for treating diabetic vascular diseases | CRABTREE ACQUISITION CO, LLC | 2006-03-16 | — | — | US | disclosed |
| US-20050090487-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | ATHEROGENICS, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | VCAM1, ICAM1, SELL | TSHR 4156/4885ALDH1A1 100/4885SMN1; SMN2 3786/4885 |
| US-20060058268-A1 | Compounds and methods for treating diabetic vascular diseases | REN, SLC5A2, SLC5A1 | TSHR 3773/4885ALDH1A1 246/4885SMN1; SMN2 496/4885 |
| US-20050090487-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | TSHR 4156/4885ALDH1A1 100/4885SMN1; SMN2 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.